EPHA2 and pachyonychia congenita: The group identified ephrine type-A receptor 2 (EphA2) as a candidate EV biomarker that was significantly overexpressed in PC cell lines using LC–MS based proteomics and bioinformatics approach, and demonstrated its effectiveness in distinguishing early stage PC patients from CP patients with an AUC of 0.94 and from healthy individuals with an AUC of 0.96.